Research Highlights:

• An analysis of health data for more than 44 million births in the U.S. found that pregnant women with pre-existing high blood pressure before pregnancy or high blood pressure diagnosed prior to the first 20 weeks of pregnancy, known as chronic hypertension, were linked to being 30% more likely to deliver an infant with critical congenital heart disease, the most severe form of heart defects, compared to women with normal blood pressure before and during pregnancy.
• Women with either Type 1 or Type 2 diabetes prior to pregnancy were associated with a 48% increased risk of having babies with severe heart defects compared to women without diabetes. 
• Gestational hypertension, or high blood pressure diagnosed after 20 weeks of pregnancy, was also associated with a slightly higher risk of critical congenital heart disease among the infants. However, eclampsia was not significantly associated with critical congenital heart disease.
• Note: The study featured in this news release is a research abstract. Abstracts presented at American Heart Association’s scientific meetings are not peer-reviewed, and the findings are considered preliminary until published as a full manuscript in a peer-reviewed scientific journal.

Embargoed until 4 a.m. CT/5 a.m. ET, Monday, Nov. 2, 2026

November 2, 2026 (NEWMEDIAWIRE) - DALLAS - Women with chronic hypertension (high blood pressure before pregnancy or diagnosed before 20 weeks of pregnancy) were associated with a 30% higher risk of having a baby with critical congenital heart disease, the most severe form of heart defects, when compared to women with normal blood pressure before and during pregnancy, according to new independent, preliminary research to be presented at the American Heart Association’s Scientific Sessions 2026. The meeting, Nov. 6-9, in Chicago, is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science.

High blood pressure during pregnancy is defined as systolic blood pressure (the top number) of 140 mm Hg or higher and diastolic blood pressure (the bottom number) of 90 mm Hg or higher. According to the American Heart Association/American College of Cardiology 2025 High Blood Pressure Guideline, high blood pressure affects approximately 16% of pregnancies. It is a leading cause of serious health complications and death for both pregnant individuals and their infants worldwide.

Types of high blood pressure in pregnancy that were included in this study were chronic (preexisting before pregnancy  or diagnosed prior to 20 weeks of pregnancy); gestational (diagnosed at 20 weeks of pregnancy or later); chronic with gestational (high blood pressure before or during the first 20 weeks of pregnancy that continues to rise and/or leads to complications); and eclampsia (severe hypertension diagnosed after 20 weeks of pregnancy that includes seizures and other complications and requires emergency treatment).

This study explored maternal health factors to evaluate the potential association between high blood pressure-related disorders during pregnancy and the risk of critical congenital heart disease (CCHD), the most severe type of  congenital heart disease, also called congenital heart defects. Infants with CCHD require surgery or catheter placement during the first year of life and continued cardiac specialty care.

The analysis found that maternal hypertension became increasingly common during the study period. The prevalence increased by nearly 48% - rising from approximately 9.4% of pregnancies in 2018 to 13.9% in 2024. The prevalence of critical congenital heart disease also increased about 10% during the same time period, from 5.8 cases per 10,000 births in 2018 to 6.4 cases per 10,000 births in 2023-2024 - representing nearly 4,000 infants in the U.S. each year.

“Our findings suggest that maternal heart health before and during pregnancy may have a particularly important relationship with fetal heart development,” said study author Saad Ur Rahman, M.D., chief cardiology fellow in the division of cardiovascular medicine at Lahey Clinic of Beth Israel Lahey Health in Burlington, Massachusetts. “These results emphasize the importance of monitoring blood pressure, discussing heart health with clinicians and receiving appropriate care before and during pregnancy to reduce the risk of fetal heart defects.”

What are the study’s main findings?

• Out of more than 44 million live births in the U.S. from 2018-2024, nearly 28,000 infants (0.06%) were diagnosed with critical congenital heart disease. Approximately 1.5% of the cases were linked to chronic or gestational hypertension.
• Chronic hypertension during pregnancy was associated with a 30% higher risk of critical congenital heart disease for the infant, compared to infants born from pregnancies where the mother did not have any type of high blood pressure.
• Women with either Type 1 or Type 2 diabetes prior to pregnancy had a 48% increased risk of having babies with severe heart defects compared to women without diabetes. 
• Women who developed gestational hypertension were had an 8% increased likelihood of having babies with critical congenital heart disease.
• Eclampsia was not significantly associated with critical congenital heart disease.

“Future studies should explore the biological mechanisms that may explain the link between maternal high blood pressure and CCHD, as well as examine whether CCHD risk is influenced by the timing, severity and treatment of high blood pressure during pregnancy,” said Rahman. 

“This study adds to a growing body of evidence linking maternal health and the intrauterine environment with fetal cardiovascular development,” said Flora Nuñez Gallegos, M.D., M.P.H., a pediatric cardiologist at University of California San Francisco and a member of the American Heart Association’s Council on Lifelong Congenital Heart Disease and Heart Health in the Young (the Young Hearts Council). “Although the absolute risk of critical congenital heart disease remains low, these findings highlight the importance of identifying and managing chronic hypertension before and during pregnancy. The association with an infant’s risk of critical congenital heart disease was stronger for chronic hypertension than for gestational hypertension, emphasizing the importance of maternal health even before pregnancy begins.”

Study details, background, design and limitations:

• The study used the CDC’s National Vital Statistics System (NVSS) U.S. Natality Public Use Files, a nationwide database of U.S. birth-certificate records of over 44 million live births from 2018 through 2024.
• Categories of blood pressure disorders during pregnancy detailed in this study included: no hypertension, chronic hypertension, gestational hypertension, chronic plus gestational hypertension, and eclampsia.  
• Analyses accounted for and adjusted for other individual factors, such as maternal demographics, Type 1 or Type 2 diabetes, smoking status, pregnancy history and pregnancy length.
• The study authors noted that the observational design limits conclusions to identifying associations rather than direct causation between chronic hypertension and CCHD.
• Another limitation is that the study used national birth certificate data, which does not capture several factors that may influence the results. These include genetic factors, maternal health history, prenatal imaging, the timing of high blood pressure during pregnancy, whether blood pressure treatment was received, how well blood pressure was controlled during pregnancy, and how consistently and for how long treatment was followed.

Co-authors, disclosures and funding sources are listed in the abstract.

Statements and conclusions of studies that are presented at the American Heart Association’s scientific meetings are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. Abstracts presented at the Association’s scientific meetings are not peer-reviewed, rather, they are curated by independent review panels and are considered based on the potential to add to the diversity of scientific issues and views discussed at the meeting. The findings are considered preliminary until published as a full manuscript in a peer-reviewed scientific journal.

The Association receives more than 85% of its revenue from sources other than corporations. These sources include contributions from individuals, foundations and estates, as well as investment earnings and revenue from the sale of our educational materials. Corporations (including pharmaceutical, device manufacturers and other companies) also make donations to the Association. The Association has strict policies to prevent any donations from influencing its science content and policy positions. Overall financial information is available here.

Additional Resources:

• Multimedia, including video interview clips with American Heart Association volunteer expert, Flora Nuñez Gallegos, M.D., M.P.H., is available on the right column of the release link.
• Spanish news release
• Link to abstract; and the American Heart Association’s Scientific Sessions 2026 Online Program Planner
• American Heart Association/ACC Guideline news release: New high blood pressure guideline emphasizes prevention, early treatment to reduce CVD risk (Aug. 2025)
• American Heart Association Scientific Statement news release: Heart disease risk factors in women highlight need for increased awareness, prevention (July 2024)
• American Heart Association Scientific Statement news release: Does risk for heart disease start before birth? (Feb. 2023)
• American Heart Association health information: Preeclampsia and High Blood Pressure
• American Heart Association Fact Sheet: Preeclampsia, High Blood Pressure and Maternal Health
• About Scientific Sessions 2026
• For more news at the American Heart Association’s Scientific Sessions 2026, follow us on X @HeartNews, #ScientificSessions26

###

About the American Heart Association

The American Heart Association is a relentless force for a world of longer, healthier lives. Dedicated to ensuring equitable health in all communities, the organization has been a leading source of health information for more than one hundred years. Supported by more than 35 million volunteers globally, we fund groundbreaking research, advocate for the public’s health, and provide critical resources to save and improve lives affected by cardiovascular disease and stroke. By driving breakthroughs and implementing proven solutions in science, policy, and care, we work tirelessly to advance health and transform lives every day. Connect with us on heart.org, Facebook, X or by calling 1-800-AHA-USA1.

For Media Inquiries and American Heart Association Expert Perspective: 214-706-1173

American Heart Association Communications & Media Relations in Dallas: ahacommunications@heart.org

Amanda Ebert: Amanda.Ebert@heart.org

For Public Inquiries: 1-800-AHA-USA1 (242-8721)

heart.org and stroke.org